EUVIMEDEUVIMED entdecken
Crossref

Risk of Major Malformations Following First‐Trimester Exposure to Cariprazine: Preliminary Data From the MGH National Pregnancy Registry for Psychiatric Medications

Adele C Viguera iD, Marlene P Freeman, Ella K Slaby, Ana M Manuelian, Peter Gaccione, David Chitayat iD, Sonia Hernández-Díaz, Lee S Cohen

Bipolar Disorders · 2026-08 · 28 (5)

DOI: 10.1111/bdi.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bipolar Disorders, online erschienen am 03.07.2026. Verfasst von Adele C Viguera und 7 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Pregnancy Trimester, First, Antipsychotic Agents, Abnormalities, Drug-Induced, Piperazines. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Alkermes, Eisai, Otsuka Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Systematically collected pregnancy safety data for cariprazine have been lacking, despite growing use of this medication across psychiatric indications. The goal of this analysis was to determine the risk of major malformations among infants of mothers with psychiatric illness who used cariprazine during the first trimester of pregnancy compared to unexposed controls.

Methods

The National Pregnancy Registry for Psychiatric Medications (NPRPM) is a prospective pharmacovigilance program in which pregnant women with psychiatric diagnoses are enrolled during pregnancy and followed through the postpartum period. Labor and delivery and pediatric medical records are reviewed for evidence of major malformations followed by final adjudication by a dysmorphologist blinded to medication exposure. Infants with first‐trimester exposure to cariprazine were compared to controls not exposed to second‐generation antipsychotic medications.

Results

As of September 9, 2025, N = 4,125 have enrolled in the study. Of those enrolled, 58 cariprazine‐exposed infants and 2,098 infants in the comparison group were eligible for inclusion in this analysis. There were no major malformations in the cariprazine‐exposed group (absolute risk 0.00%; 95% confidence interval, 0.00%–6.16%) compared to 32 infants with major malformations in the control group (1.53%; 1.05%–2.15%).

Conclusions

In this prospective cohort, 0 of 58 infants exposed to cariprazine during the first trimester had major malformations, compared with 32 of 2,098 (1.53%) unexposed infants. Although these data are preliminary and cannot rule out modest teratogenic effects, they are nonetheless important to provide to health care providers and the public, as cariprazine use has been rising among women of reproductive age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy Trimester, FirstAntipsychotic AgentsAbnormalities, Drug-InducedPiperazinesPrenatal Exposure Delayed EffectsPregnancy ComplicationsMental DisordersHumansFemalePregnancyRegistriesAdultProspective StudiesPharmacovigilanceInfant, Newborn

Stichwörter der Autor:innen

atypical antipsychoticsbipolar disordercariprazinepregnancypsychotic disordersreproductive psychiatryteratogenicity

Substanzen

Antipsychotic AgentscariprazinePiperazines

Autor:innen und Institutionen

  • Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health, Boston, Massachusetts, USA.
  • Cleveland Clinic, Cleveland Clinic Neurological Institute, Cleveland, Ohio, USA.
  • University of Toronto, Toronto, Ontario, Canada.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

ORCID-Profile: Adele C Viguera, David Chitayat

Förderung

  • Alkermes
  • Eisai
  • Otsuka Pharmaceutical
  • Supernus Pharmaceuticals
  • Bristol-Myers Squibb
  • Sage Therapeutics

Zitieren

APA

Viguera, A. C., Freeman, M. P., Slaby, E. K., Manuelian, A. M., Gaccione, P., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2026). Risk of Major Malformations Following First‐Trimester Exposure to Cariprazine: Preliminary Data From the MGH National Pregnancy Registry for Psychiatric Medications. Bipolar Disorders, 28(5). https://doi.org/10.1111/bdi.70138

Vancouver

Viguera AC, Freeman MP, Slaby EK, Manuelian AM, Gaccione P, Chitayat D, et al. Risk of Major Malformations Following First‐Trimester Exposure to Cariprazine: Preliminary Data From the MGH National Pregnancy Registry for Psychiatric Medications. Bipolar Disorders. 2026;28(5). doi:10.1111/bdi.70138

BibTeX
@article{Viguera2026,
  author = {Viguera, Adele C and Freeman, Marlene P and Slaby, Ella K and Manuelian, Ana M and Gaccione, Peter and Chitayat, David and Hernández-Díaz, Sonia and Cohen, Lee S},
  title = {Risk of Major Malformations Following First‐Trimester Exposure to Cariprazine: Preliminary Data From the MGH National Pregnancy Registry for Psychiatric Medications},
  journal = {Bipolar Disorders},
  year = {2026},
  volume = {28},
  number = {5},
  doi = {10.1111/bdi.70138}
}
Kostenlos starten →